Prochlorperazine

證據等級: L5

預測適應症: 10 個

Prochlorperazine: From Nausea/Vomiting and Psychotic Symptom Control to Manic Bipolar Affective Disorder

Note on candidate selection: The evidence pack’s top-scored prediction (rank 1, retinal dystrophy with or without extraocular anomalies, score 99.998%) and ranks 2–9 are all congenital/genetic disorders. The evidence pack’s own analyst notes for every one of these state there is no mechanistic link and no drug-specific literature or trial support — they are flagged as likely knowledge-graph co-occurrence noise (decision_stage: S0, recommendation: Hold). This report therefore focuses on rank 10, manic bipolar affective disorder, the only prediction with a biologically plausible mechanism, a decision_stage of S1, and supporting literature.

One-Sentence Summary

Prochlorperazine is a phenothiazine-class D2-receptor antagonist, used clinically for nausea/vomiting and psychotic symptom control. The TxGNN model predicts possible efficacy in manic bipolar affective disorder, a mechanistically plausible extension of its antipsychotic class effect, but the evidence base is currently limited to 0 clinical trials and 12 pieces of literature — mostly class-level reviews and case reports rather than drug-specific trial data.

Quick Overview

Item	Content
Original Indication	Not available in ARTG records — prochlorperazine is not currently marketed in Australia. Per evidence-pack rationale text, it is used clinically for nausea/vomiting and psychotic symptom control.
Predicted New Indication	Manic Bipolar Affective Disorder
TxGNN Prediction Score	99.98%
Evidence Level	L3
Australia Market Status	Not Marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed structured mechanism-of-action data is not available for prochlorperazine in this evidence pack (flagged as a High-severity data gap). Based on known information in the evidence pack’s own rationale, prochlorperazine is a phenothiazine-class dopamine D2-receptor antagonist, in the same pharmacological family as first-generation antipsychotics such as chlorpromazine and haloperidol.

D2 antagonism is the established mechanism behind the antimanic efficacy of first-generation antipsychotics in acute mania — dopamine blockade reduces the excess dopaminergic transmission associated with manic states. This gives the TxGNN prediction a degree of biological plausibility that is absent from the model’s higher-scored but mechanistically unrelated congenital-disease predictions.

However, prochlorperazine itself is not established as a first-line (or even routinely used) antimanic agent — it is used almost exclusively for nausea/vomiting and short-term psychotic/anxiety symptom control. The supporting literature reflects this: it is largely class-level evidence (phenothiazines/antipsychotics in general) rather than trial data on prochlorperazine specifically in mania. One historical case report (1959) does describe a confusional reaction to prochlorperazine in a patient with mild manic-depressive illness, but this documents an adverse psychiatric effect during use for another indication, not therapeutic efficacy in mania.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
13617778	1959	Case Report	Annales médico-psychologiques	Confusional dream-like episode caused by prochlorperazine in a patient with mild manic-depressive illness — direct drug-specific observation, but describes an adverse effect, not antimanic efficacy
19461391	2009	Review	J Psychiatric Practice	Use and safety of antipsychotic drugs (class review) during pregnancy, incl. bipolar-spectrum indications
15863814	2005	Review	American Journal of Psychiatry	Quetiapine discontinuation syndrome — antipsychotic class context
26819726	2015	Pharmacovigilance/Adverse Event Analysis	J Pharmaceutical Health Care and Sciences	FAERS analysis of hyperglycaemic adverse events across dopamine-antagonist antipsychotics used in schizophrenia and bipolar disorder
235013	1975	Case Report	Journal of the Neurological Sciences	Tardive dyskinesia induced by phenothiazines, treated with pimozide — class-level toxicity data
6069087	1967	Case Series	Neurology	Spontaneous seizures and EEG changes during phenothiazine therapy
4238455	1969	Review	Clinical Pharmacology and Therapeutics	General review of psychotherapeutic drug use, including phenothiazines
14233737	1964	Review/Survey	American Journal of Psychiatry	ECT combined with phenothiazines and reserpine — historical psychiatric management survey
14242542	1965	Review	Obstetrics and Gynecology	Management of severe psychologic disorders of the puerperium, including phenothiazine use
14222730	1964	Review	L’Encéphale	Psychodysleptic manifestations occurring during treatment with psycholeptic drugs

Australia Market Information

Prochlorperazine currently has no ARTG entries and is not marketed in Australia (0 licences on record).

Safety Considerations

No structured safety data (key warnings, contraindications, or drug interactions) is currently available for this candidate, and this is flagged as a Blocking data gap (DG001) in the evidence pack. As prochlorperazine is not currently ARTG-listed, there is no Australian TGA-approved Product Information to reference; safety review would need to draw on comparable overseas regulatory documentation (e.g. UK/US product information) as an interim source.

Conclusion and Next Steps

Decision: Hold

Rationale: Prochlorperazine is not currently marketed in Australia, and the manic bipolar affective disorder prediction — while mechanistically plausible — is supported only by class-level (phenothiazine/antipsychotic) literature rather than drug-specific trial evidence; no clinical trials exist for this indication. The model’s higher-scored predictions (ranks 1–9) were assessed by the evidence pack itself as likely artifacts with no mechanistic or literature support and are not viable candidates.

To proceed, the following is needed:

Confirmed original mechanism-of-action data (DG002, High severity)
TGA/TFDA-equivalent product warnings and contraindications (DG001, Blocking severity) — required before any S1 safety screening can occur
An Australian market-entry regulatory pathway assessment, since there are currently 0 ARTG entries
Prospective or retrospective clinical evidence evaluating prochlorperazine specifically (not the phenothiazine class generally) in mania/bipolar disorder
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.